Insider Selling: Outset Medical (NASDAQ:OM) CEO Sells 11,794 Shares of Stock

Outset Medical, Inc. (NASDAQ:OM) CEO Leslie Trigg sold 11,794 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total transaction of $60,385.28. Following the completion of the transaction, the chief executive officer owned 107,823 shares in the company, valued at $552,053.76. This represents a 9.86% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Leslie Trigg also recently made the following trade(s):

• On Wednesday, January 21st, Leslie Trigg sold 2,120 shares of Outset Medical stock. The shares were sold at an average price of $5.05, for a total value of $10,706.00.
• On Wednesday, January 7th, Leslie Trigg sold 1,795 shares of Outset Medical stock. The shares were sold at an average price of $4.27, for a total value of $7,664.65.
• On Monday, November 17th, Leslie Trigg sold 916 shares of Outset Medical stock. The stock was sold at an average price of $4.60, for a total transaction of $4,213.60.

Outset Medical Price Performance

OM stock traded up $0.15 during trading on Wednesday, reaching $5.20. The company had a trading volume of 256,678 shares, compared to its average volume of 1,737,004. The company has a debt-to-equity ratio of 0.69, a current ratio of 7.09 and a quick ratio of 5.77. Outset Medical, Inc. has a 52 week low of $3.10 and a 52 week high of $21.98. The business has a 50 day moving average of $4.34 and a 200 day moving average of $11.07.

Analyst Ratings Changes

A number of brokerages have issued reports on OM. Stifel Nicolaus lowered their price objective on Outset Medical from $14.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, January 7th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Outset Medical in a research report on Monday, December 29th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $7.00 price target on shares of Outset Medical in a research note on Wednesday, December 17th. Wall Street Zen lowered shares of Outset Medical from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Finally, BTIG Research reiterated a “buy” rating and issued a $17.00 target price on shares of Outset Medical in a research note on Tuesday, December 16th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $10.67.

Hedge Funds Weigh In On Outset Medical

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Legal & General Group Plc bought a new position in Outset Medical in the 2nd quarter worth approximately $34,000. Ameritas Investment Partners Inc. purchased a new position in shares of Outset Medical during the 2nd quarter worth about $35,000. BNP Paribas Financial Markets grew its stake in shares of Outset Medical by 7,013.8% during the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after buying an additional 2,034 shares during the last quarter. Police & Firemen s Retirement System of New Jersey purchased a new position in Outset Medical during the 2nd quarter valued at $78,000. Finally, New York State Common Retirement Fund bought a new position in Outset Medical in the 2nd quarter valued at $108,000.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.